Patients in the OAD plus insulin group were more likely to report ≥1 hypoglycemia symptom (83.3% [244/293]) compared with those in the sulfonylurea without insulin group (69.9% [172/246]) or the nonsulfonylurea OAD without insulin group (59.1% [162/274]; P < 0.001). The gene discussed is INS; the disease is Hypoglycemia.